secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K/A
Filed at:   2023-12-20T23:59:59+00:00
Accession:  0001140361-23-058659
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant files pro forma financials for $7.1B Telavant sale to Roche; gain of $5.3B
--------------------------------------------------------------------------------

- Roivant sold its 75% stake in Telavant to Roche for ~$7.1B cash plus $150M milestone for Phase 3 trial initiation.
- Pro forma cash and cash equivalents at Sep 30, 2023: $6.6B, up from $1.4B historical.
- Pro forma net income attributable to Roivant for FY Mar 2023: $4.3B vs historical net loss of $1.1B.
- Pro forma net loss for H1 Sep 2023: $552M vs historical loss of $596M; reduction from eliminated Telavant R&D.
- Transaction accounted for as sale of nonfinancial assets; $5.3B gain recognized.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123058659/0001140361-23-058659-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123058659/ef20017039_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-058659

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer